Rifabutin

利福布汀

Report date: 2025/02/08 11:46:43
NME

Base Information

Drug NameRifabutin
Drug Alias Name利福布丁rifabutinerifabutina利福有丁利福喷叮 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBacterial DNA-directed RNA polymerase inhibitors
TargetsBacterial DNA-directed RNA polymerase
Therapy Area/IndicationsTuberculosis, Multidrug-ResistantMycobacterium avium-intracellulare InfectionMycobacterium Infections, Nontuberculous
Global Approved IndicationsTuberculosis, Multidrug-ResistantMycobacterium avium-intracellulare Infection
Approved Indications in ChinaTuberculosis, Multidrug-Resistant
Original Approved Country/TerritoryUnited States
Original Approved Date1992/12/23
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncSichuan Med-Shine Pharmaceutical Co Ltd
Inactive CompaniesThe University Of Texas Health Science Center At Tyler
Active IndicationsTuberculosis, Multidrug-ResistantMycobacterium avium-intracellulare Infection
Inactive IndicationsMycobacterium Infections, Nontuberculous

Other Information

ATC CodeJ04AB04
Related LinksWikipediaDrugBankKEGG